1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sensorion
  6. News
  7. Summary
    ALSEN   FR0012596468

SENSORION

(ALSEN)
  Report
Real-time Quote. Real-time Euronext Paris - 05/27 11:35:16 am
0.4285 EUR   +2.02%
04/15SENSORION : Inside Information / Other news releases
PU
04/14SENSORION : Proxy Statments
CO
03/17Sensorion SA Provides Update on SENS-401
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

01/17/2022 | 01:30am EDT

Sensorion SA reports results from the 115-patient Phase 2 AUDIBLE-S study of SENS-401 (Arazasetron), for the treatment of sudden sensorineural hearing loss (‘SSNHL’). SENS-401 was safe and well tolerated, however, it did not meet the primary endpoint of 15 dB, a significant improvement in pure tone audiometry (PTA, dB) in the affected ear from baseline in comparison to placebo at the end of the four-week treatment period. A sub-analysis in participants with hearing threshold > 80dB, representing those with severe hearing loss, showed a better response compared to placebo at the two doses. This subgroup accounted for 30% of the overall study population. These results confirm the data obtained in preclinical model of severe noise induced hearing loss. Sensorion will continue to evaluate the data from the AUDIBLE-S study and the secondary endpoints results will be released mid-March. It will outline plans for the development of SENS-401 SSNHL at that point.


© S&P Capital IQ 2022
All news about SENSORION
04/15SENSORION : Inside Information / Other news releases
PU
04/14SENSORION : Proxy Statments
CO
03/17Sensorion SA Provides Update on SENS-401
CI
01/17SENSORION : Inside Information / Other news releases
PU
01/17Sensorion's Hearing Loss Therapy Fails in Mid-Stage Study
MT
01/17Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss
CI
01/04Sensorion Appoints Aniz Girach as Independent Board Member Replacing Jean-François Mori..
CI
01/04SENSORION : Nomination
CO
2021Sensorion SA Announces Executive Changes
CI
2021Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in Janua..
CI
More news
Financials
Sales 2021 4,15 M 4,44 M 4,44 M
Net income 2021 -19,0 M -20,3 M -20,3 M
Net cash 2021 0,69 M 0,74 M 0,74 M
P/E ratio 2021 -1,79x
Yield 2021 -
Capitalization 34,1 M 36,6 M 36,6 M
EV / Sales 2021 8,07x
EV / Sales 2022 7,74x
Nbr of Employees 39
Free-Float 50,7%
Chart SENSORION
Duration : Period :
Sensorion Technical Analysis Chart | ALSEN | FR0012596468 | MarketScreener
Technical analysis trends SENSORION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,43 €
Average target price 3,77 €
Spread / Average Target 779%
EPS Revisions
Managers and Directors
Nawal Ouzren Chief Executive Officer & Director
Scott D. Myers Chairman
Géraldine Honnet Chief Medical Officer
Nora Yang Chief Scientific Officer
Otmane Boussif Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
SENSORION-77.75%37
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478